Eikon Therapeutics (EIKN)
Develops oncology therapies using live-cell single-molecule tracking and in-licensed clinical assets.
Something off on this page? Send us feedback.
Develops oncology therapies with a proprietary single-molecule-tracking platform and a portfolio that combines internally derived and in-licensed clinical assets. It is a development-stage biopharmaceutical organization whose work spans research, engineering, and clinical development.
Develops oncology therapies around proprietary single-molecule tracking, a live-cell discovery platform that combines custom-engineered super-resolution microscopy, automation, data science, and software. The company pairs internally derived programs with in-licensed clinical-stage candidates.
Operations are globally integrated, with facilities in California, New Jersey, and New York. Its work spans research, engineering, platform development, clinical development, collaboration agreements, and intellectual property.
The business is shaped by clinical development and financing needs. It has incurred net losses and negative operating cash flows since inception, and may seek capital through equity, debt, licenses, collaborations, or other arrangements.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $531.6M · Total debt $252.2M · Total assets $779.6M · Shareholders' equity $466.5M
- Revenue
- $0
- Operating income
- −$93.4M
- Net income
- −$88.4M
No dividends on record.
| Institutions52 holders · as of Mar 31, 2026 | 43.86% | 23.74M shares | |
| Otherremainder | 56.14% | 30.40M shares |
54.14M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
FMR LLCInstitution | 7.09% | 3.84M | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 6.13% | 3.32M | 13Fas of Mar 31, 2026 |
Foresite Capital Management Iv, LLCInstitution | 3.59% | 1.94M | 13Fas of Mar 31, 2026 |
Merck & Co., Inc.Institution | 3.08% | 1.67M | 13Fas of Mar 31, 2026 |
Foresite Capital Management V, LLCInstitution | 2.44% | 1.32M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- AstraZeneca (ADR)
Lynparza overlaps across ovarian, breast, pancreatic and prostate cancer
- Bristol-Myers Squibb
PD-1 regimens in advanced melanoma and metastatic NSCLC
- Pfizer
Talzenna addresses BRCA-mutated breast cancer and HRR-mutated mCRPC
- GSK (ADR)
Zejula is a PARP inhibitor in first-line maintenance for ovarian cancer
- Iovance Biotherapeutics
TIL therapy in post-PD-1 melanoma and frontline melanoma trials
- Zentalis Pharmaceuticals
Azenosertib targets cyclin E1-positive platinum-resistant ovarian cancer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Eikon Therapeutics | $11.38 | +4.60% | $616.1M | — | — | — | — |
| AstraZeneca (ADR) | $164.21 | +1.58% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Pfizer | $28.98 | −0.17% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| GSK (ADR) | $50.89 | +0.92% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Iovance Biotherapeutics | $8.68 | +0.52% | $3.85B | — | — | 11.8 | +65.7% |
| Zentalis Pharmaceuticals | $3.79 | +0.26% | $268.4M | — | — | — | — |
| Median | 20.0 | 10.5 | 2.8 | +5.7% |